Cannell & Spears’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$269K Sell
1,663
-3
-0.2% -$500 ﹤0.01% 378
2026
Q2
$316K Hold
1,666
– – 0.01% 364
2026
Q1
$329K Sell
1,666
-1
-0.1% -$193 0.01% 348
2025
Q4
$306K Hold
1,667
– – 0.01% 341
2025
Q3
$256K Buy
1,667
+176
+12% +$26.6K ﹤0.01% 361
2025
Q2
$208K Buy
1,491
+11
+0.7% +$1.54K ﹤0.01% 367
2025
Q1
$218K Buy
+1,480
New +$214K ﹤0.01% 357
2024
Q4
– Sell
-2,063
Closed -$321K – 397
2024
Q3
$321K Buy
2,063
+408
+25% +$65.9K 0.01% 334
2024
Q2
$258K Hold
1,655
– – 0.01% 319
2024
Q1
$224K Hold
1,655
– – ﹤0.01% 351
2023
Q4
$223K Hold
1,655
– – 0.02% 198
2023
Q3
$224K Hold
1,655
– – 0.02% 188
2023
Q2
$237K Hold
1,655
– – 0.02% 200
2023
Q1
$230K Hold
1,655
– – 0.02% 204
2022
Q4
$224K Buy
+1,655
New +$208K 0.02% 203
2022
Q3
– Sell
-1,655
Closed -$219K – 194
2022
Q2
$219K Hold
1,655
– – 0.02% 189
2022
Q1
$220K Buy
+1,655
New +$198K 0.02% 211
2015
Q3
– Sell
-3,656
Closed -$233K – 133
2015
Q2
$233K Buy
3,656
+28
+0.8% +$1.92K 0.03% 129
2015
Q1
$248K Buy
+3,628
New +$252K 0.03% 121

Other funds holding AZN

Cannell & Spears's AZN Position: Q3 2026 in Review

Cannell & Spears reduced its AstraZeneca (AZN) stake by 0.18% in Q3 2026, selling an estimated $500 and leaving 1,663 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #378.

Cannell & Spears first reported a position in AZN in Q1 2015 and has held it in 19 quarters since. The position peaked at $329K in Q1 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Cannell & Spears held 1,663 shares of AstraZeneca worth $269K as of Q3 2026.
  • Cannell & Spears sold 3 AstraZeneca shares in Q3 2026, an estimated $500.
  • AstraZeneca made up ﹤0.01% of Cannell & Spears's portfolio in Q3 2026, its #378 holding.
  • Cannell & Spears first reported a position in AstraZeneca in Q1 2015 and has held it in 19 quarters since.
  • Cannell & Spears's AstraZeneca position peaked at $329K in Q1 2026.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Cannell & Spears's 13F filing for Q3 2026, filed 12 Nov 2026.